Which statement best describes the evidence for BCAA enriched enteral formulas in hepatic failure?

• A. They have clear, consistent benefits in all hepatic failure patients.
• B. Randomized trials show mixed results; use limited to patients refractory to standard therapy due to cost and limited evidence.
• C. They are recommended for all patients with hepatic failure.
• D. They are contraindicated in hepatic encephalopathy.

Answer: (B)